Tate, R.Britton, E.Webb, S.Ramage, C.Bernhardt, J.Cass, A.French, C.J.Groom, K.Herkes, R.Katz, C.Mol, B.W.Simes, R.J.Sonderlund, N.Butcher, B.E.Zalcberg, J.R.2021-06-242021-06-242021Medical Journal of Australia, 2021; 214(4):159-1610025-729X1326-5377http://hdl.handle.net/2440/130937Abstract not availableen© 2021 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.Clinical trials as topic; cost-benefit analysis; economics; medicalThe value proposition of investigator-initiated clinical trials conducted by networksJournal article100003786110.5694/mja2.50935000619575500001569483Mol, B.W. [0000-0001-6887-0262] [0000-0001-8337-550X]